CODING TUMOUR MORPHOLOGY. Otto Visser

Similar documents
The European Commission s science and knowledge service. Joint Research Centre

Format Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te

DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #

CODING PRIMARY SITE. Nadya Dimitrova

FINALIZED SEER SINQ QUESTIONS

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture

FINALIZED SEER SINQ S NOVEMBER 2011

Other Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1

ICD-O CODING Third Edition

Instructions for Coding Grade for 2014+

ONCOLOGY. Csaba Bödör. Department of Pathology and Experimental Cancer Research november 19., ÁOK, III.

incidence rate x 100,000/year

2010 Update. NAACCR Webinar Series 1 4/1/2010. Agenda. Access to 2010 Information. CSv2. Collecting Cancer Data: Soft Tissue Sarcoma

Kentucky Cancer Registry Spring Training 2017

Appendix 4: WHO Classification of Tumours of the pancreas 17

Methoden / Methods inc. ICCC-3 105

Cancer in Estonia 2014

CLIC Sargent Eligibility Criteria

ICD-O CODING Third Edition

2018 ICD-O-3 Updates in Table Format with Annotation for Reference

Introduction to Basic Oncology

NEOPLASIA. 3. Which of the following tumour is benign a. Chondrosarcoma b. Osteochondroma c. Chondroblastoma d. Ewing s tumour e.

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

Introduction to ICD-O-3 coding rules

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System

Pathology of Sarcoma ELEANOR CHEN, MD, PHD, ASSISTANT PROFESSOR DEPARTMENT OF PATHOLOGY UNIVERSITY OF WASHINGTON

Chapter 4. Histological groups

List of Available TMAs in the PRN

Overview of 2010 Hong Kong Cancer Statistics

CASEFINDING. KCR Abstractor s Training

ICD-O Morphology code. R=Rare Tier Tumour ICD-O Topography code C30.0, C31

Radiation Oncology Study Guide

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval

2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:

WHI Extension Appendix A, Form Report of Cancer Outcome (Ver. 8.2) Page 1

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Neoplasia literally means "new growth.

Cerebral Parenchymal Lesions: I. Metastatic Neoplasms

Cancer Association of South Africa (CANSA)

Quiz. b. 4 High grade c. 9 Unknown

CANCER Uncontrolled Cell Division

ANNUAL CANCER REGISTRY REPORT-2005

What is Cancer? Understanding the basics of

WHI Extension Section 8 Outcomes Page 8-85

came from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary

Mississippi Cancer Registry Reporting Manual Revised 2016

Testicular Germ Cell Tumors; A Simplistic Approach

DUSTURBANCES OF GROWTH. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L8 Uz: Musa

Neoplasms/Lymphoma/Leukemia

Chapter 3. Neoplasms. Copyright 2015 Cengage Learning.

FINALIZED SEER SINQ QUESTIONS April July, 2017

Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence

FINALIZED SEER SINQ S MAY 2012

Not For Sale. Alternative Billing Codes (ABC Codes) Clinical Care Classification (CCC) System

2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill

Colon and Rectum: 2018 Solid Tumor Rules

CNS TUMORS. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

Chapter 1 MAGNITUDE AND LEADING SITES OF CANCER

Breast Pathology. Breast Development

VULVAR CARCINOMA. Page 1 of 5

Abdulrahman Alhanbali. Bahaa Najjar. Maha shomaf

FINALIZED SEER SINQ QUESTIONS

NEOPLASIA-I CANCER. Nam Deuk Kim, Ph.D.

The International Classification of Diseases for Oncology (ICD-O) is

Uropathology January Jon Oxley

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary

3 cell types in the normal ovary

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING

COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING

Rare Breast Tumours. 1. Breast Tumours. 1.1 General Results. 1.2 Incidence

Neoplasms of the Heart, Pericardium, and Great Vessels Histopathology Reporting Guide

Breast pathology. 2nd Department of Pathology Semmelweis University

Overview of 2009 Hong Kong Cancer Statistics

A neoplasm is defined as "an abnormal tissue proliferation, which exceeds that of adjacent normal tissue. This proliferation continues even after

TUMOR,NEOPLASM. Pathology Department, Zhejiang University School of Medicine,

2014 International Journal of Medical Science Research and Practice available on

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

Comprehensive cancer cover

Frequency of non specific morphology codes (ICD O M) within the National Cancer Data Repository ( ) for cancer in Teenagers and Young Adults

Hazelinks - Cancer incidence analysis (First data extraction)

The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light.

Quiz The main functions of the ovaries are a. To produce oocytes b. To produce estrogen c. To produce progesterone d.

Icd 10 code lung ca with mets to bone

HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT 2011

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

7/29/ Grade Coding Instructions ICD-O-3 Updates. Outline. Introduction to Coding Grade for 2014+

2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.

Aviva Group Protection Our guide to cancer

Comprehensive cancer cover

- is a common disease - 1 person in 3 can expect to contract cancer at some stage in their life -1 person in 5 can expect to die from it

Histological Typing Of Cancer And Precancer Of The Oral Mucosa

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Recent advances in breast cancers

Multiple Primary and Histology Site Specific Coding Rules BREAST. FLORIDA CANCER DATA SYSTEM MPH Breast Site Specific Coding Rules

Icd 10 code metastatic adenocarcinoma endometrial

Icd-10 code for small cell lung cancer

Transcription:

CODING TUMOUR MORPHOLOGY Otto Visser

INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show no resemblance to normal tissues. Normal tissue epithelium squamous cell epithelium fat tissue blood vessel Cancer carcinoma squamous cell carcinoma liposarcoma (lipo- = fat) angiosarcoma (angio- = vessel)

TECHNIQUES TO DETERMINE MORPHOLOGY Traditional pathology: cytology, histology (descriptive) Immunohistochemistry (surface antigens) Cytogenetic tests (chromosomes) Molecular tests (DNA) Whole genome sequencing

WHY IS THE MORPHOLOGY IMPORTANT? Epidemiological: Different morphologies may be related to different etiological factors For example: squamous cell carcinoma and adenocarcinoma of the oesophagus Therapeutical: Different morphologies may require different treatments For example: small cell carcinoma and adenocarcinoma of the oesophagus, haematological malignancies

CARCINOMA OR SARCOMA During embryogenesis three germ layers are formed: Endoderm (or entoderm) Mesoderm Ectoderm (Germ cells)

CARCINOMA OR SARCOMA Germ layer endoderm mesoderm Organs formed from the germ layer Gastro-intestinal tract, pharynx, lungs, thyroid Soft tissue, bone, cartilage, serous membranes (mesothelium), notochord, blood & lymphatic system, genitourinary system Predominant type of cancer Adenocarcinoma Sarcoma Mesothelioma Chordoma Lymphosarcoma ectoderm Skin (epidermis), mouth, eye Skin appendices, breast neuro-ectoderm: Central nervous system, retina, melanocytes Squamous cell carcinoma Adenocarcinoma Glioma Melanoma

GERM CELLS Germ cells Germ cells are omnipotent (= all types of tissues can be formed) In an embryo germ cells are formed in the midline (from brain to sacrum) When the gonads are being formed, the germ cells migrate to the gonads (ovary, testis) Some germ cells do not migrate to the gonads and may in later life give rise to cancer outside the gonads

BENIGN OR MALIGNANT What makes a tumour a malignant tumour? The potency to metastasize via blood or lymph vessels Carcinoma Invasion of the basal membrane (there are no blood or lymph vessels in the epithelium) /0 (benign), /2 (non-invasive) or /3 (invasive) Sarcoma (non-carcinoma) Tumour characteristics (number of cell divisions, differentiation grade, cell atypia, etc.) The presence of metastases /0 (benign), /1 (borderline) or /3 (malignant)

ICD-O CODING RULES

ICD-O-3 MORPHOLOGY CODING RULES Rule F. Rule G. Rule H. Rule J. Rule K. Behaviour code in morphology Grading or differentiation code Site-associated morphology terms Compound morphology diagnoses Coding multiple morphology terms

RULE F. BEHAVIOUR CODE IN MORPHOLOGY (THE MATRIX PRINCIPLE ) Use the appropriate 5th digit behaviour code even if the exact term is not listed in ICD-O. / Cell type Behavior Differentiation

RULE F. BEHAVIOUR CODE IN MORPHOLOGY Behaviour of a tumour is the way it acts within the body Codes: /0 benign the tumour grows in place without the potential for spread; /1 uncertain whether benign or malignant /2 non-invasive or in situ the tumour is malignant, but still growing in place (does not invade the basal membrane) /3 malignant, primary site the tumour invades surrounding tissues Pathologists may use also /6 (metastatic cancer) or /9 (uncertain whether or metastatic ) code as /3 in CR

RULE F. BEHAVIOUR CODE IN MORPHOLOGY The Matrix 8010/0_ Epithelial tumor, benign 8010/2_ Intraepithelial carcinoma, NOS 8010/3_ Epithelial tumor, malignant (Carcinoma, NOS) 8800/0_ 8800/1_ 8800/3_ Soft tissue tumor, benign Soft tissue tumor, borderline Soft tissue tumor, malignant (Sarcoma, NOS)

RULE F. BEHAVIOUR CODE IN MORPHOLOGY Implied rule: It is okay to change the behaviour code to accurately report what the pathologist said. Example Pathology report states malignant adenomyoepithelioma ICD-O-3 only lists 8983/0 Adenomyoepithelioma. Code 8983/3 with behaviour code 3 to indicate that this tumour is malignant.

RULE F. BEHAVIOUR CODE IN MORPHOLOGY Most cancer registries collect only /2 Carcinoma in situ; non-invasive; non-infiltrating; intraepithelial /3 Malignant, primary site (invasive) If a diagnosis comes from a metastatic site, the cancer registry records the primary site and the morphology with behavior /3. Example: Pathology report says: metastatic adenocarcinoma in lung biopsy. Coded as C34.9 8140/6 on report. Cancer registry reports case as unknown primary site, C80.9 8140/3

RULE G. GRADING OR DIFFERENTIATION CODE Assign the highest grade or differentiation code described in the diagnostic statement. / Cell type Behavior Differentiation

RULE G. GRADING OR DIFFERENTIATION CODE Histological grading and differentiation for malignant tumors describes how much or how little a tumor resembles the normal tissue from which it arose (codes 1 to 4 and 9). Cell origin/lineage for leukemias and lymphomas (codes 5 to 8 and 9) Codes: 1 Grade I, well differentiated 2 Grade II, moderately differentiated 3 Grade III, poorly differentiated 4 Grade IV, undifferentiated, anaplastic 5 T-cell 6 B-cell (7 Null cell, Non T-non B) 8 NK (natural killer) cell 9 grade, differentiation or cell type not determined, not stated or not applicable

RULE G. GRADING OR DIFFERENTIATION CODE OF SOLID CANCERS (EXCL. CNS) Implied rule: Code to the higher grade. Example: moderately to poorly differentiated adenocarcinoma of prostate Moderately differentiated = grade 2 Poorly differentiated = grade 3 Code diagnosis as 8140/33

RULE G. GRADING OR DIFFERENTIATION CODE OF SOLID CANCERS (EXCL. CNS) Use the 6th digit grade or differentiation code as a check where the terminology is included in the morphology term. Implied rule: double code any statement of grade in the diagnostic term. Example: undifferentiated carcinoma Undifferentiated carcinoma= 8020/3 Undifferentiated = 4 Code diagnosis as 8020/34

EXCEPTION: CNS TUMOURS Central Nervous System tumours follow a slightly different system (table 27 in ICD-O) WHO Grade I (benign or borderline malignant) WHO Grade II ( low grade ) WHO Grade III ( anaplastic ) WHO Grade IV Examples: oligodendroglioma, NOS = 9450/32 anaplastic astrocytoma =9401/33 glioblastoma =9440/34

RULE G. CELL ORIGIN FOR LYMPHATIC MALIGNANCIES Implied rule: Never use the grade but always use the cell origin. Example: follicular B-cell lymphoma, grade 2 Follicular lymphoma, grade 2 = 9691/3 B-cell origin = code 6 Code diagnosis as 9691/36

RULE H. SITE-ASSOCIATED MORPHOLOGY TERMS Use the topography code provided when a topographic site is not stated in the diagnosis. This topography code should be disregarded if the tumor is known to arise at another site. Suggested site code In parenthesis ( ) after morphology term Most common site associated with neoplasm Examples M-8330/3 Adenocarcinoma, follicular (C73.9 {thyroid}) M-9700/3 Mycosis fungoides (C44._ {skin})

RULE H. SITE-ASSOCIATED MORPHOLOGY TERMS Examples of terms that include a root word mentioning a site Nephroblastoma, NOS (C64.9 kidney) Thymoma, NOS (C37.9 thymus) Cloacogenic carcinoma (C21.2 cloacogenic zone of anal canal) Bronchiolar carcinoma (C34._ bronchioles of lung) Hepatocellular carcinoma (C22.0 liver) No suggested site code is listed when malignancy could appear in many sites, such as adenocarcinoma, NOS

RULE H. SITE-ASSOCIATED MORPHOLOGY TERMS If a site is given that is different from the site indicated by the suggested site code, use the site code appropriate to the diagnosis. Example: infiltrating duct carcinoma, head of pancreas 8500/3 Infiltrating duct carcinoma (C50._) Suggested site code is breast ignore this based on diagnosis! Head of pancreas = C25.0 Code diagnosis as C25.0 8500/3

RULE H. SITE-ASSOCIATED MORPHOLOGY TERMS Implied rule: Use the suggested site code as a guide to code the primary site. If the site stated in the pathology report is different, code what the pathology report states.

HETEROGENEITY WITHIN 1 TUMOUR mutation mutation mutation

RULE J. COMPOUND MORPHOLOGY DIAGNOSES Change the order of word roots in a compound term if the term is not listed in ICD-O-3. Compound words have multiple root words Myxofibrosarcoma not in ICD-O-3 Break into word roots Myxo / fibro / sarcoma Change around word roots, then look up new term Fibromyxosarcoma 8811/3 Chondro-osteosarcoma Osteochondrosarcoma 9180/3

RULE K. CODING MULTIPLE MORPHOLOGY TERMS When no single code includes all diagnostic terms, use the numerically higher code number if the diagnosis of a single tumor includes two modifying adjectives with different code numbers. Implied rule: Code to higher code number if there is no combination code.

RULE K. CODING MULTIPLE MORPHOLOGY TERMS Examples Basaloid squamous cell carcinoma, large cell No combination code Squamous cell carcinoma, large cell 8072/3 Basaloid squamous cell carcinoma 8083/3 Code morphology to higher number 8083/3 Papillary and tubular adenocarcinoma Papillary adenocarcinoma 8260/3 Tubular adenocarcinoma 8211/3 Code morphology to 8255/3 (Adenocarcinoma with mixed subtypes)

RULE K. CODING MULTIPLE MORPHOLOGY TERMS Look for a code that represents the combined morphology. Common combinations may have a unique code. Usually say mixed or combined or and Mixed embryonal carcinoma and teratoma = teratocarcinoma 9081/3 Ductal carcinoma and lobular carcinoma 8522/3 Compound terms Carcinosarcoma 8980/3 Adenocarcinoma and squamous carcinoma = adenosquamous carcinoma 8560/3 Small cell-large cell carcinoma 8045/3

HAEMATOLOGICAL MALIGNANCIES for solid tumours the topography is the most discriminative factor breast, lung, skin for haematological malignancies the morphology is the most discriminative factor Hodgkin lymphoma, mantle cell lymphoma, peripheral T- cell lymphoma

HAEMATOLOGICAL MALIGNANCIES Always code the most specific code (not necessarily the highest code) Take into account specific diagnostics, such as immunohistochemistry and cytogenetics

HOW TO CODE Break phrase into topography and morphology Look up morphology first Use up all the words in the phrase Add 5 th and 6 th digit codes Look up topography

CODING EXAMPLE 1 Diagnosis: Poorly differentiated hepato-cellular carcinoma of right lobe of liver What is it (morphology)? Hepatocellular carcinoma, NOS (C22.0): 8170/3 Suggested site code is included in index Liver, right lobe: C22.0 Liver, NOS What else do we know? Poorly differentiated: /_3 Complete codes: C22.0 8170/33

CODING EXAMPLE 2 Diagnosis: Moderately differentiated adenocarcinoma of prostate What is it (morphology)? Adenocarcinoma [not otherwise specified]: 8140/3 What else do we know? Moderately differentiated: /_2 Where did it start (topography)? Prostate: C61.9 Complete codes: C61.9 8140/32